Human Nuclear Factor, Erythroid Derived 2 Like 2 (NFE2L2) Protein

Product Graph
234€ (2 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Nuclear Factor, Erythroid Derived 2 Like 2 (NFE2L2) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx680398
tested applications
SDS-PAGE

Description

Human Nuclear Factor, Erythroid Derived 2 Like 2 (NFE2L2) Protein is a recombinant protein expressed in E. coli.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Nuclear Factor, Erythroid Derived 2 Like 2 (NFE2L2)
Host
E. coli
Origin
Human
Conjugation
Unconjugated
Expression
Recombinant
Purity
> 85% (SDS-PAGE)
Size 1
2 µg
Size 2
10 µg
Size 3
100 µg
Form
Liquid
Tested Applications
SDS-PAGE
Availability
Shipped within 5-10 working days.
Dry Ice
No
Background
Protein NFE2L2
Status
RUO
Note
This product is for research use only.   Not for human consumption, cosmetic, therapeutic or diagnostic use.

Descripción

Related Products

EH3417

Human NFE2L2 (Nuclear Factor, Erythroid Derived 2 Like 2) ELISA Kit

Ver Producto
ER0666

Rat Nfe2l2 (Nuclear Factor, Erythroid Derived 2 Like Protein 2) ELISA Kit

Ver Producto
FNab05855

NFE2L2 antibody

NRF2, also named as NFE2L2, belongs to the bZIP family and CNC subfamily. It is a transcription activator that binds to antioxidant response(ARE) elements in the promoter regions of target genes. NRF2 is important for the coordinated up-regulation of genes in response to oxidative stress. It may be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region.Nrf2 is a key player in the regulation of genes encoding for many antioxidative response enzymes.The expression of NRF2 may be induced under oxidative stress(PMID:14567983).In lung cancer, Nrf2 activation in malignant cells has been associated with tumor progression and chemotherapy resistance(PMID:20534738). Identifying patients with abnormal NRF2 expression may be important for selection for chemotherapy in NSCLC.

Ver Producto